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Abstract
Background: Nef is a 27 KDa HIV-1 accessory protein. It downregulates CD4 from infected cell surface, a
mechanism critical for efficient viral replication and pathogenicity. Agents that antagonize the Nef-mediated CD4
downregulation may offer a new class of drug to combat HIV infection and disease. TPCK (N-a-p-tosyl-L-
phenylalanine chloromethyl ketone) and TLCK (N-a-p-tosyl-L-lysine chloromethyl ketone) are alkylation reagents
that chemically modify the side chain of His or Cys residues in a protein. In search of chemicals that inhibit Nef
function, we discovered that TPCK and TLCK alkylated HIV Nef.
Methods: Nef modification by TPCK was demonstrated on reducing SDS-PAGE. The specific cysteine residues
modified were determined by site-directed mutagenesis and mass spectrometry (MS). The effect of TPCK
modification on Nef-CD4 interaction was studied using fluorescence titration of a synthetic CD4 tail peptide with
recombinant Nef-His protein. The conformational change of Nef-His protein upon TPCK-modification was
monitored using CD spectrometry
Results: Incubation of Nef-transfected T cells, or recombinant Nef-His protein, with TPCK resulted in mobility shift
of Nef on SDS-PAGE. Mutagenesis analysis indicated that the modification occurred at Cys55 and Cys206 in Nef.
Mass spectrometry demonstrated that the modification was a covalent attachment (alkylation) of TPCK at Cys55
and Cys206. Cys55 is next to the CD4 binding motif (A56W57L58) in Nef required for Nef-mediated CD4
downregulation and for AIDS development. This implies that the addition of a bulky TPCK molecule to Nef at
Cys55 would impair Nef function and reduce HIV pathogenicity. As expected, Cys55 modification reduced the
strength of the interaction between Nef-His and CD4 tail peptide by 50%.
Conclusions: Our data suggest that this Cys55-specific alkylation mechanism may be exploited to develop a new
class of anti HIV drugs.
Background
Nef proteins of primate lentiviruses, HIV-1, HIV-2 and
SIV, are abundantly expressed in the early phase of
HIV-1 infection and play a crucial role in the pathogeni-
city of HIV-1 and the development of AIDS [1-8]. One
prominent piece of evidence is that HIV-1 strains iso-
lated from some long-term survivors carried deletions
or truncations of nef exclusively [9,10]. The pathological
roles of Nef in the development of AIDS have been
attributed to several Nef biological activities, including
downregulation of the viral primary receptor CD4 [11]
and downregulation of the cell surface expression of
class-I major histocompatibility complex (MHC-I)
[12,13]. Nef also affects T cell activation and apoptosis
in favor the viral replication by engaging several signal-
ing molecules, such as Vav, Pak2, ASK1 and Src family
kinases [14-18] (for reviews, see [19,20]). Nef has no
known catalytic activity; it acts essentially as a connector
to link CD4, MHC-I, and possibly some other target
molecules to adaptor protein (AP) complexes AP-1, AP-
2 or AP-3, responsible for the endocytosis and subse-
quent lysosomal degradation of Nef’s targets. We found
that Nef-mediated CD4 downregulation is AP-2 depen-
dent and required an ubiquitinated lysine residue K144
in HIV-1 Nef [21,22]. The structure of HIV-1 Nef has
been established by NMR and X-ray crystallography
[23-25] (see [26] for a review). HIV-1 Nef protein con-
sists of a conserved core domain of about 120 residues
and two flexible regions - the N-terminus 68 amino
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(V148-L181) located in the C-terminal region. The HIV
protease cleavage site C55AW57LEA [27] and CD4 bind-
ing motif (A56W57L58) [28] are located in Nef N-term-
inal region. Nef is myristoylated at a Gly residue (G2) in
the N-terminus, which mediates the membrane associa-
tion of Nef [29]. The core domain is a a-b globular
structure responsible for Nef binding to SH3 domain-
containing proteins [16,30,31]. The loop in the C-term-
inal region contains the dileucine motif ExxxLL160,
which interacts with adaptor protein complexes AP-1, 2,
3 [32-34].
TPCK (N-a-p-tosyl-L-phenylalanine chloromethyl
ketone) and TLCK (N-a-p-tosyl-L-lysine chloromethyl
ketone) are alkylation reagents that can chemically mod-
ify side chains of specific His or Cys residues in some
proteins. It is known that TPCK modifies His in the
reactive center of serine protease chymotrypsin and
trypsin, resulting in enzymatic inhibition (EC50 of 20
μMa n d8 0μM, respectively) [35,36]. TPCK and TLCK
also alkylate the sulfhydryl group of the Cys residue in
several other proteins, including protein kinase C
[37,38], cAMP-dependent kinase [39,40], HPV-18 E7
[41] and human ETS 1 oncoprotein [42]. Alkylation of
Cys side chains makes HPV-18 E7 [41] and human ETS
1 oncoprotein [42] migrate faster on SDS-PAGE.
Methods
Cells, antibodies and chemicals
SV40 T antigen-transfected human leukemic Jurkat T
cells (JTAg) were cultured in RPMI medium supplemen-
ted with 10% FCS. For transient expression, plasmid
DNA was transfected into the cells using Lipofectamine
2000™(Invitrogen). Anti-HIV-1 Nef rabbit serum was
obtained from NIH AIDS Research and Reference
Reagent Program. N-tosyl-L-phenylalanine chloromethyl
ketone (TPCK), NA-p-tosyl-L-lysine chloromethyl
ketone (TLCK) and N-CBZ-Phe-Ala fluoromethyl
ketone (Z-FA-FMK) were purchased from Sigma (Saint
Louis, MO).
Plasmids
HIV-1 Nef (NA7)-GFP plasmid kindly provided by Dr. J.
Skowronski was subcloned into pcDNA3 to express un-
tagged wt Nef (NA7). Nef (G2G3/AA) mutant was gen-
erated by PCR mutagenesis as described before [43]. Nef
(NL4-3) was PCR subcloned into pcDNA3 vector with
the template of HIV-1 (NL4-3) provirion from NIH
AIDS Research and Reference Reagent Program. Nef
Cys-to-Ala mutants C55/A, C142/A, C206/A, C55&206/
A, C55&142/A, C142&206/A and C55&C142&C206/A
(Cys free) were generated by PCR mutagenesis with wt
Nef (NA7) plasmid template using Multi-Quick Change
Mutagenesis kit (Stratagene). For E. coli cell expression,
wt Nef and Nef mutants were subcloned into pET-30a
(+) vector (Novagen) at Nde I/Not I sites. All mutations
generated in this study were confirmed by DNA
sequencing.
Analysis of Nef modification in TPCK- or TLCK-treated
JTAg cells
Analysis was performed using Nef (NA7) transfected
JTAg cells unless otherwise specified. Cells were trans-
fected with Nef plasmid DNA for 16-20 h and treated
with TPCK/TLCK (10 μg/ml) for 30 min. Cells (2 ×
10
5)w e r eb o i l e di n2 5μl2×S D Ss a m p l eb u f f e ra n d
loaded to 11% reducing SDS-PAGE. Nef protein was
detected by immunoblotting with polyclonal anti-Nef
(1:10,000 dilution) at RT for 2 h or at 4°C overnight,
followed by ECL anti-rabbit Ab (1:10,000) at RT for 1 h.
Nef-His protein preparation and in vitro modification
Plasmid encoding Nef-His in pET-30a (+) vector was
transformed into E. coli BL21 cells. The transformed
cells were grown in LB medium at 37°C for 16 h, 1: 10
diluted with fresh LB, and induced with IPTG (1 mM)
for 3 hours. Four hundred ml of cells were pelleted,
washed with PBS and lysed by sonication. Nef-His pro-
tein was isolated with a HisTrap column (Amersham
Biosciences) or using Ni-NTA agarose beads (QIAGEN).
The beads were washed three times in 20 mM Imida-
zole/PBS. Nef-His was eluted with 250 mM Imidazole,
adjusted with PBS to the concentration of UV absor-
bance (A280) = 1.0, and kept at -20°C before use. For
in vitro modification, freshly prepared Nef-His was incu-
bated with TPCK (10 μg / m l )a tR Tf o r3 0m i n .T w e n t y
μl of samples was resolved by SDS-PAGE. The gels were
stained with Coomassie Blue or immunoblotted with
anti-Nef.
Mass spectrometry
Nef-His protein was in vitro modified with TPCK as
described above. The completion of the modification
was confirmed by SDS-PAGE. Fifty μg of the un-modi-
fied and TPCK-modified Nef-His proteins were analyzed
by MS to determine the molecular weight. For trypsin-
digestion, 20 μg of Nef-His was denatured in 0.1 M
ammonium bicarbonate at 55°C for 30 min and then
digested at 37°C with trypsin at 1:100 (w/w). The sam-
ples were subjected to mass spectrometry (MALDI-ToF)
at the NYU medical school service center using MS
spectrometer Micromass (Waters).
Fluorescence titration of CD4 tail peptide with HIV-1 Nef
Fluorescein-labeled CD4 tail peptide (Fluorescein-
QAERMSQIKRLLSEKKT, residue 403-419) was synthe-
sized by Sigma. Fluorescence emission was recorded
with a FluoroMax-2 fluorescence spectrometer
Jin et al. AIDS Research and Therapy 2010, 7:26
http://www.aidsrestherapy.com/content/7/1/26
Page 2 of 10(excitation at 492 nm; emission at 516 nm). CD4 tail
peptide of 1.0 μM in PBS was analyzed in a stirred cuv-
ette at 25°C. Data were collected after 30 min incuba-
tion with Nef-His. Controls incubated with PBS did not
show reduction in fluorescence. Experimental signals
were expressed as the percentage of fluorescence reduc-
tion averaged from three independent measurements.
The signals were plotted against total Nef concentration.
CD spectrum of Nef-His
Nef-His protein of 100 μM (~2.5 mg/ml) in PBS, pH
7.4, was subjected to CD spectrometry analysis. Far-UV
CD measurement at 20°C was made on an Aviv 202 CD
spectrometer (Lakewood, NJ) in the department of
chemistry of NYU. Data were the average of 4-6 accu-
mulations, using scanning wavelength of 260-195 nm,
speed of 20 nm/min, bandwidth of 1 nm, and response
time of 0.5 s. Data were plotted using the SigmaPlot
software.
Results
TPCK and TLCK modified HIV-1 Nef expressed in culture T
cells
JTAg cells were transfected with plasmids encoding
HIV-1 Nef NA7 or NL4-3 and treated with one of the
three alkylating reagents, TPCK, TLCK, or Z-FA-FMK.
Fig.1A shows that TPCK- or TLCK-treatment altered
the mobility of both Nef NA7 and Nef NL4-3 proteins
on SDS-PAGE. About 20-30% Nef proteins migrated
faster with the treatments (indicated by the letter “F”)
whereas a small fraction of Nef protein migrated slower
(indicated by the letter “S”), which was more noticeable
with TLCK than with TPCK. In contrast, treatment with
similar doses of Z-FA-FMK did not affect the mobility
of Nef protein on SDS-PAGE (Fig.1A). TPCK and
TLCK contain chloromethyl ketone whereas Z-FA-FMK
contains fluoromethyl ketone (boxed in Fig.1B). The
results suggest that Nef proteins may be specifically
modified by TPCK and TLCK. TPCK/TLCK at a dose
of 1-2 μg/ml (~5-10 μM) was effective in the modifica-
tion. This dose is lower than the EC50 of TPCK (20
μM) and TLCK (80 μM) in their serine protease inhibi-
tion (sigma product information), suggesting a higher
reaction specificity of TPCK/TLCK with Nef than with
serine proteases. The modification is independent of Nef
myristoylation and membrane association since the myr-
istoylation-defective Nef (G2G3/AA) mutant was also
modified with TPCK (Fig.1A bottom).
TPCK modified Nef at Cys55 and Cys206
It was reported that TPCK-treatment altered the mobi-
lity of HPV-18 E7 and human ETS 1 oncoprotein on
SDS-PAGE as a result of Cys alkylation [41,42]. HIV-1
Nef contains two conserved Cys residues (Cys55 and
Cys142) and a partially conserved C-terminal Cys
(Cys206) [44]. To find out whether Nef was also modi-
fied at Cys residues, we examined the mobility of
TPCK-treated Nef Cys mutants on SDS-PAGE. Fig. 2
shows that TPCK-treatment did not cause any mobility
shift of Cys-free Nef mutant (upper left panel), suggest-
ing that Cys residues were the residues to be modified.
Double Cys mutant C55&206/A showed no mobility
Figure 1 Treatment of Nef transfected T cells with TPCK or
TLCK altered the mobility of Nef on SDS-PAGE. (A) Anti-Nef
immunoblotting of Nef proteins from TPCK, TLCK or Z-FA-FMK
treated cells. JTAg cells were transfected with Nef NA7 (upper
panel), Nef NL4-3 (middle panel) or NA7 (G2G3/AA), treated with
TPCK, TLCK or Z-FA-FMK for 30 min as indicated. The whole cell
lysates were immunoblotted with anti-Nef. Arrows indicate the
faster (F) or slower (S) migrated Nef proteins. (B) Structures of TPCK,
TLCK and Z-FA-FMK. The boxed atoms are the alkylating groups
reacting with specific His or Cys residues in substrate proteins.
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&/or Cys206, but not Cys142, were the residues modi-
fied. Further more, single cysteine mutant C55/A
migrated slower on SDS-PAGE, indicating that the mod-
ification at Cys206 resulted in a slow migration form of
Nef (C206M) whereas Nef mutant C206/A migrated fas-
ter on SDS-PAGE (bottom panels), indicating that the
modification at Cys55 resulted in a faster migration
form (C55M). The migration patterns of Nef mutant
C142&206/A (Cys55 modified) and C55&142/A (Cys206
modified) were the same as that of C206/A and C55/A.
Taken together, the mutagenesis data suggest that
Cys55 and Cys 206 but not C142 and His residues are
modified by TPCK. This conclusion is directly proved
by the following MS analysis.
TPCK modified recombinant Nef-His protein in vitro and
the modification appeared to be dependent on Nef
conformation
Next we asked whether TPCK-modification of Nef is a
direct chemical reaction. The E. coli expressed, isolated
Nef-His protein was incubated with TPCK in PBS. Fig.
3A shows that Nef-His protein was modified with TPCK
in vitro, resulting in a faster mobility shift on SDS-
PAGE. The results indicated that the modification is a
direct chemical reaction between Nef and TPCK. Nota-
bly, we found that the freshly prepared Nef-His protein
was modified efficiently, with a yield of ~80 to 95%. But
the modification yield was greatly decreased if Nef-His
protein in PBS had been kept at 4°C for 1-2 days before
Figure 2 TPCK-modification of Nef mutants with Cys55, Cys142, and/or Cys206 substituted with Ala. Plasmid encoding Nef mutant C55/
A, C206/A, C142&206/A, C55&206/A, C55&142/A or C55&C142&c206/A (Cys free) were transfected into JTAg cells. TPCK modification was
determined as described in Fig. 1. Arrows indicate the Cys206-modified (C206M), Cys55-modified (C55M) and the un-modified Nef (un) proteins.
Figure 3 In vitro modification of Nef-His protein by TPCK E. coli-
expressed Nef-His protein was isolated using Ni-beads as described
in Methods. Twenty μl of freshly prepared Nef-His protein at the
concentration of ~0.5 μg/μl was incubated with TPCK in PBS at RT
for 30 min and then resolved by SDS-PAGE. The gels were stained
with Coomassie Blue. (A) TPCK-modification of the freshly prepared
Nef-His protein at different TPCK concentrations. (B) TPCK-
modification of the Nef-His protein pre-incubated in PBS at different
temperatures for different length of times.
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or 37°C, an 8 or 4 h pre-incubation was enough to
almost abrogate the modification (Fig. 3B). As shown in
the figure, Nef-His was not degraded during the incuba-
tion. Since it is known that the isolated recombinant
Nef protein is unstable and undergo conformational
change &/or aggregation at higher concentrations [24],
the results suggested that a potential conformational
change of Nef may affect its modification with TPCK. It
is possible that the overexpressed Nef protein in culture
cells also undergoes conformational change &/or aggre-
gation, which could explain why Nef was only partial
modified with TPCK (Fig.1). Supporting this notion, we
observed that alkylation efficiency of Nef in culture cells
was reduced when the new Nef protein synthesis was
stopped by addition of cycloheximide and MG132 in
cell culture for several hours (data not shown).
MS analysis proved that TPCK was covalently bound to
Cys 55 and Cys 206 but not to His residues
To prove that TPCK is covalently bound to Cys55 and
Cys206 and to rule out that TPCK may modify some
other Nef residues unaffecting Nef’s mobility, we ana-
lyzed the TPCK-modification of Nef-His by mass spec-
trometry (MS). Fig. 4A shows the molecular weight of
untreated and TPCK-treated Nef-His determined by
MS. The peak of untreated Nef-His is 24386 Dalton
(TPCK-) whereas TPCK-treated Nef-His is 25011 Dal-
ton (TPCK+). The 631 Dalton difference equals the
molecular weight of two TPCK molecules (2 × 352 Dal-
ton) minus two HCl molecules (2 × 36.5 Dalton), indi-
cating that each Nef molecule was covalently bound
with two TPCK molecules. To prove that TPCK was
bound to Cys55 and Cys206, we did a tryptic mapping
(Fig. 4B). Amino acid sequence of Nef-His predicts that
tryptic peptide of 1430 Da (P1430) contains Cys206,
tryptic peptide of 4787 Da (P4787) contains Cys55, and
tryptic peptide of 1263 Da (P1263) contains Cys142. All
these peptides were detected (indicated by arrows) in
untreated Nef-His. With TPCK-modification, P1430 and
P4787 were converted to P1745 and P5100. TPCK-treat-
ment did not affect P1263, indicating that Cys142 is not
alkylated. Note, we have to use a high sensitivity scale
for detection of P4787 (up right panel) due to its low
UV absorbance. With the attachment of TPCK (N-a-p-
tosyl-L-phenylalanine chloromethyl ketone) - a highly
UV detectable chemical, P5100 (4787+TPCK) and
P1745 (1430+TPCK) (bottom panels) exhibited a much
higher UV absorbance. We also sequenced the tryptic
peptide P1715 that contains the very C-terminal His-tag
a n dC y s 2 0 6( F i g .4 C ) .T h er e s u l t ss h o w e dt h a tn o n eo f
the His residues in His-tag was alkylated, whereas
Cys206 was. Residue B of the peptide (Cys206, circled in
Fig. 4C) had a molecular weight of 418 Da, exactly
equal to that of a one TPCK-alkylated Cys. Thus, the
collective MS data proved that TPCK alkylates Cys55
and Cys206 but not Cys142 or any His residues.
TPCK alkylation at Cys55 severely impaired Nef’s
interaction with CD4 tail peptide
Cys55 is next to Nef motif A56W57L58, a site impli-
cated in the interaction of Nef with CD4, Nef-mediated
CD4 downregulation and the onset of AIDS [9,10,28].
To ask whether the attachment of a bulky TPCK mole-
cule to Cys55 affects Nef-CD4 interaction, we performed
an in vitro CD4-Nef binding assay following a published
protocol [45]. In the assay, a fluorescein-labeled 17
amino acid CD4 tail peptide was incubated with Nef-His
or TPCK modified Nef-His proteins at increase concen-
trations. Quenching of the fluorescence emission from
the label CD4 peptide by Nef-His proteins was mea-
sured as the results of CD4-Nef interaction [45]. Fig. 5
(left panel) compares the titration curve of the unmodi-
fied wt Nef-His with that of TPCK-modified Nef-His.
The results showed that the fluorescence emission was
quenched by 11.6% with unmodified Nef-His protein
(10 μM) whereas was quenched by 4.9% with TPCK-
modified Nef-His, indicating that TPCK-modification
resulted in more than 50% of decrease in the strength of
Nef-CD4 interaction. To confirm that the effects are
C55 modification specific, we also compared the titra-
tion curve of the unmodified Nef mutant (C55/A)-His
with that of TPCK-treated Nef (C55/A)-His. Fig. 5 (right
panel) shows that the titration curves of the untreated
and treated (C55/A)-His were quite similar. At 10 μM
concentration, the level of quench was 10.6% and 9.8%
for untreated and treated, respectively, confirming that
the effects are depended on modification of Nef C55.
We concluded that the alkylation at Cys55 will greatly
impair Nef-CD4 interaction and, therefore, would
weaken HIV-1’s pathogenicity. In addition, the fluores-
cence reduction by wt Nef-His was 11.6% compared
with 10.6% by Nef (C55/A)-His, suggesting that C55A
mutation itself may have a weak effects on Nef-CD4
interaction.
CD spectrometry data indicated a moderate Nef
conformational change after TPCK alkylation
To ask whether alkylation alters the solution structure of
Nef, we compared the CD spectrometry of Nef-His pro-
teins unmodified or modified with TPCK (Fig. 6). The
CD spectrometry showed that Nef has an overall a-b
structure with an absorbance of a-helix at 208 nm and
absorbance of b-sheet at 216-220 nm. TPCK alkylation
did not result in a shift of the absorbance wavelength
(nm), suggesting that there was no global change in the
overall a-b structure. However, the a-helix absorbance at
~208 nm apparently became weaker, suggesting a less
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Page 5 of 10Figure 4 Mass Spectrometry (MS) of the unmodified and TPCK-modified Nef-His proteins. (A) MS- determination of the molecular weight
of the unmodified (TPCK-) and modified (TPCK+) Nef-His proteins. (B) Tryptic mapping of Nef-His proteins by MS. Unmodified (top panel) or
TPCK-modified Nef-His proteins (bottom panel) were excised from SDS PAGE gels, digested by trypsin and injected into Micromass (Waters) for
MS (MALDI-ToF). Arrows indicate the tryptic peptides containing cysteine: P1263 (C142), P1430 (C206) and P4787 (C55) from unmodified Nef-His
(top panel), and P1263 (C142), P1745 (C206) and P5100 (C55) from the TPCK-modified Nef-His (bottom panel). (C) MS sequencing of the
modified C-terminal peptide (P1745). Residue 10
B is the modified Cys206. Three residues Glu, Leu and Glu between Nef and His-tag are
translated from the vector poly-linker region. Note, different sensitivity scales are used to show the unmodified C55 (P4787) and TPCK modified
C55 (P5100).
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Page 6 of 10Figure 5 Titration of a fluorescein labeled CD4 tail peptide with HIV Nef-His proteins.1 . 0μM of the CD4 peptide in PBS was incubated
for 30 min with Nef-His proteins at the concentrations from 0.01 to 10 μM in 0.5 ml volume. Fluorescence emission was recorded with a
FluoroMax-2 fluorescence spectrometer (excitation at 492 nm; emission at 516 nm) in a stirred cuvatte at 25°C. Reduction in fluorescence
emission after incubation with a protein is expressed as the percentage of the fluorescence before incubation. The reduction in fluorescence is
plotted against Nef-His concentration. The values are the average of three repeats. Left panel: Fluorescence reduction of the CD4 peptide after
incubation with unalkylated Nef (wt)-His (black circle) or TPCK-alkylated Nef (wt)-His (white square). Right panel: Fluorescence reduction of the
CD4 peptide incubated with the untreated Nef (C55A)-His (black circle) or TPCK-treated Nef (C55A)-His (white square).
Figure 6 CD spectra of untreated Nef-His or TPCK alkylated Nef-His. The experiment was described in Methods. Samples were scanned at
260-195 nm (far-UV) at 20°C on an Aviv 202 CD spectrometer (Lakewood, NJ). Acquired data were plotted using the SigmaPlot software.
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with our observation that TPCK-treatment reduced Nef
half-life in cultured T cells (not shown). Therefore, in
addition to attenuation of Nef-CD4 interaction, this may
be as a second mechanism for alkylation to undermine
Nef’s function.
Discussion
This study demonstrated that alkylation reagents, TPCK
and TLCK, modify HIV-1 accessory protein Nef in live
T cells and in vitro. Mutagenesis and MS analysis indi-
cated that TPCK-modification of Nef is an alkylation
reaction that resulted in the covalent bound of TPCK
molecule to the side chains of Cys55 and Cys206 resi-
d u e s( F i g .1 ,2 ,3 ,4 ) .S e v e r a ll i n e so fe v i d e n c es u g g e s t
that the reaction is quite specific: (1) TPCK and TLCK
have been used as specific serine protease inhibitors.
The EC50 values of TPCK and TLCK alkylation on Nef
are lower than that on chymotrypsin and trypsin, sug-
gesting higher alkylation specificity than that of serine
proteases. (2) Z-FA-FMK, a structurally very similar
alkylation reagent, is inactive in modifying Nef (Fig. 1).
(3) TPCK reacts with Cys but not with His residues,
including those in the C-terminal His-tag, fully accessi-
ble to TPCK (Fig. 4). (4) TPCK appears to alkylate
Cys55 more efficiently than to Cys206 (Fig.1).
The mechanism by which TPCK alkylates Cys residue
is much less understood than the mechanism by which
it alkylates His residues. It is well known that TPCK
inhibits serine proteases by alkylating the His side chain
at an enzyme’ reactive center [35,36]. This understand-
ing has rationalized the use of TPCK in signal transduc-
tion studies. In addition, some recent reports implicated
the effects of alkylation at Cys, rather than at His resi-
dues [46-48]. However, how TPCK reacts with specific
His or Cys is unclear. Our study showed that in case of
Nef, the accessibility of Cys residues for TPCK appeared
important but not sufficient for TPCK-modification.
The TPCK-modified Cys55 and Cys206 are both accessi-
ble, locating in Nef N-terminal flexible region and at the
C-terminal end, respectively, whereas the none-modified
C142 is buried in the Nef core [26]. However, accessibil-
ity cannot explain why TPCK did not react with any His
residues despite that there are nine His residues in Nef,
of which several are accessible. They include His 40 in
the N-terminal flexible region and His166/His171 in the
C-terminal loop region. In addition, TPCK did not react
with any His residues in the C-terminal His-tag. Prob-
ably the residues surrounding the reactive Cys or His
are involved in the interaction with TPCK side chain,
thus contributed to alkylation specificity.
Cys55 is next to Nef motif A56W57L58, a site impor-
tant for Nef-CD4 interaction and development of AIDS
[28]. The motif is also the cleavage site for HIV protease
[27]. It is conceivable that the covalent attachment of a
bulky TPCK molecule to Cys55 would interfere with
Nef-CD4 interaction and some other Nef functions.
Fluorescence titration data indicated that TPCK-modifi-
cation indeed dramatically reduced the binding strength
of Nef to a CD4 tail peptide (Fig. 5). TPCK-modification
may have an additional mechanism against HIV-1 by
altering Nef conformation as shown by the CD spec-
trum change (Fig. 6) and making it unstable as sug-
gested by a shortened half-life of Nef in T cells also
(unpublished data). Unfortunately, current cell system is
not fit for testing anti HIV-1 activity due to technical
difficulty. TPCK only partially (50%, maximum) alkylates
wt Nef overexpressed in cultured T cells, leaving more
than half of Nef without alkylation (Fig.1). A small frac-
tion of unalkylated Nef protein is sufficient to downre-
gulate CD4. Moreover, TPCK is toxic to T cells at high
concentrations, which compromises the interpretation of
an anti HIV-1 activity.
Our finding suggests that TPCK can serve as a proto-
type of a class of drugs that retains the Cys55 modifica-
tion activity but has desired pharmacodynamic and
pharmacological properties. A 3-D structure of the
TPCK-bound Nef could guide the design and synthesis
of new compounds. In this regard, we have developed a
convenient method of generating large quantity of
TPCK-bound Nef for structure studies (Fig. 3, 4). A
comparison of such a 3-D structure with the existing
3-D model of TPCK bound to a His residue at the
catalytic center of a serine protease [49] may aid the
development of similar compounds that are specific for
cysteine over histidine or vice versa.
Conclusions
Chloromethyl ketone reagents TPCK and TLCK directly
react with Cys55 and Cys206 in Nef. TPCK alkylation at
Cys55 dramatically weakens Nef-CD4 interaction, sug-
gesting that TPCK-like small chemicals with better
pharmacokinetics and pharmacodynamics may be devel-
oped for HIV disease intervention.
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